The Cancer Biology program constitutes the foundation of basic science research of the OHSU Cancer institute. The overall goal of the Cancer Biology Program is to investigate the underlying cellular and molecular mechanisms involved in the development of cancer and in the regulation of both normal and abnormal cell growth. The scientific thrust of the program is in two related areas of investigation: Carcinogenesis/Genetic Instability and Signal Transduction. There are with 34 full and 2 associate members in the program with $25.1 million in grant funding stemming from 83 projects. Of these, 26 grants provide $7.4 million in NCI funding. Members of the Carcinogenesis/Genetic Instability group focus their studies around cell cycle control, the regulation of apoptosis, and the relationship of these events to the development of genetic instability and cancer. The members of the Signal Transduction group focus their studies around general signaling mechanisms of relevance to regulation of normal and cancer cell growth: the integrated function of growth factors and their receptors, kinase-mediated signaling phenomena, and the regulation of transcription that lies downstream of the aforementioned events. Because of the seamless nature of cellular regulation that is relevant to the cancer problem, there is a great deal of overlap between the research interests of the two groups. These shared interests have led to an abundance of collaborations and interactivity among the members of the Cancer Biology program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA069533-09
Application #
7107585
Study Section
Subcommittee G - Education (NCI)
Project Start
2005-08-05
Project End
2010-05-31
Budget Start
2005-08-05
Budget End
2006-05-31
Support Year
9
Fiscal Year
2005
Total Cost
$9,640
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6
Li, Bingbing X; Chen, Jingjin; Chao, Bo et al. (2018) Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins. ACS Chem Biol 13:1380-1387

Showing the most recent 10 out of 277 publications